Inegy (Simvastatin, Ezetimibe)

Simvastatin blocks HMG‑CoA reductase, the enzyme responsible for cholesterol synthesis in the liver, leading to increased removal of LDL from the bloodstream. Ezetimibe inhibits the NPC1L1 transporter in the intestine, reducing the absorption of dietary and biliary cholesterol. Together they provide a complementary reduction in circulating LDL‑cholesterol.

The dose of Inegy is individualized by the prescribing clinician based on the patient’s lipid profile, treatment goals, and tolerance. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted over time.

Safety data for the combination of simvastatin and ezetimibe during pregnancy and lactation are limited. Generally, the product is avoided in pregnant or nursing women unless the potential benefit justifies the potential risk, and it should only be used under close medical supervision.

To request Inegy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Inegy combines a statin (simvastatin) with a cholesterol absorption inhibitor (ezetimibe), offering greater LDL‑cholesterol reduction than a statin alone. Compared with other fixed‑dose combinations, it provides a balance of efficacy and tolerability, but individual response and safety profiles should be evaluated by the treating physician.

Inegy tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Inegy is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include myopathy or rhabdomyolysis, which may present as unexplained muscle pain, weakness, or dark urine, and hepatotoxicity, indicated by jaundice or elevated liver enzymes. Patients should report any such symptoms promptly to their healthcare provider.

Inegy is contraindicated in patients with active liver disease, unexplained persistent elevations of hepatic transaminases, or known hypersensitivity to simvastatin, ezetimibe, or any excipients. Caution is also advised for individuals taking strong CYP3A4 inhibitors or other medications that increase statin exposure.